The Antiemetic Efficacy and the Cost-Benefit Ratio of Ondansetron Calculated with a New Approach to Health Technology Assessment (Real Cost-Benefit Index)

1992 ◽  
Vol 4 (5) ◽  
pp. 326-331 ◽  
Author(s):  
S. Tanneberger ◽  
G. Lelli ◽  
A. Martoni ◽  
E. Piana ◽  
F. Pannuti
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Cost Benefit ◽  
Health Technology ◽  
New Approach ◽  
Benefit Ratio ◽  
Real Cost ◽  
Antiemetic Efficacy ◽  
Cost Benefit Ratio ◽  
The Cost

Home Visitation Investment

PEDIATRICS ◽  
1992 ◽  
Vol 89 (1) ◽  
pp. 169-169
Author(s):  
NORMAN J. SISSMAN
Keyword(s):  
Health Care ◽  
Home Visits ◽  
Cost Benefit ◽  
Home Visitation ◽  
Benefit Ratio ◽  
Health Care Resources ◽  
Detailed Consideration ◽  
Cost Benefit Ratio ◽  
Women And Children ◽  
The Cost

To the Editor.— Two recent reviews in Pediatrics1,2 provide much interesting information on the effect of home visits on the health of women and children. However, I was disappointed not to find in either article more than token reference to the cost of the programs reviewed. In this day of increasingly scarce health care resources, we no longer have the luxury of evaluating programs such as these without detailed consideration of their cost-benefit ratio.

scholarly journals Ultrasound scan as a potential source of nosocomial and cross-infection: a literature review

2015 ◽  
Vol 48 (5) ◽  
pp. 319-323 ◽  
Author(s):  
André Hadyme Miyague ◽  
Fernando Marum Mauad ◽  
Wellington de Paula Martins ◽  
Augusto César Garcia Benedetti ◽  
Ana Elizabeth Gomes de Melo Tavares Ferreira ◽  
...  
Keyword(s):  
Literature Review ◽  
Cost Benefit ◽  
Cross Infection ◽  
Ultrasound Scan ◽  
Benefit Ratio ◽  
Source Of Infection ◽  
Potential Source ◽  
Cost Benefit Ratio ◽  
The Cost

AbstractThe authors review the main concepts regarding the importance of cleaning/disinfection of ultrasonography probes, aiming a better comprehension by practitioners and thus enabling strategies to establish a safe practice without compromising the quality of the examination and the operator productivity. In the context of biosafety, it is imperative to assume that contact with blood or body fluids represents a potential source of infection. Thus, in order to implement cleaning/disinfection practice, it is necessary to understand the principles of infection control, to consider the cost/benefit ratio of the measures to be implemented, and most importantly, to comprehend that such measures will not only benefit the health professional and the patient, but the society as a whole.

OP135 Confirmatory Versus Explorative Endpoints In Drug Approval Versus Health Technology Assessment

2017 ◽  
Vol 33 (S1) ◽  
pp. 63-64
Author(s):  
Ines Niehaus ◽  
Charalabos-Markos Dintsios
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Drug Approval ◽  
Health Technology ◽  
Benefit Assessment ◽  
Benefit Ratio ◽  
Early Benefit Assessment ◽  
The Impact ◽  
Early Benefit

INTRODUCTION:The early benefit assessment of drugs in Germany and their preceded market authorization pursue different objectives, resulting in divergent decision-making strategies. This is reflected inter alia by the diverse inclusion of confirmatory endpoints within the assessments of oncological drugs. The pharmaceutical manufacturers are facing the challenge of meeting the requirements for both evaluation processes by the available evidence and avoiding hereby negative early benefit assessments. This is mainly due to the concept of mutually relevant clinical trials.METHODS:Identification and gathering of the endpoints is based on a specifically developed guide. The extracted data from the documents of completed assessments up to July 2015 are used to estimate both separately and together the impact of explorative in relation to confirmatory endpoints on the drug approval and early benefit assessment, by contrasting the European Medicines Agency's risk-benefit-ratio and the benefit-harm-balancing of the national Health Technology Assessment (HTA) jurisdiction.RESULTS:Twenty-one of fourty-one studies’ oncological assessments could be included in the endpoint analysis. From a procedural point of view both the drug approval and the early benefit assessment seem to be not confirmatory since they include explorative endpoints as well. Yet, drug approval is in terms of quality of endpoints more confirmatory than early benefit assessment since it contains a higher proportion of primary endpoints. The latter implies only in 67 percent of the assessments a primary endpoint to be relevant for the benefit-harm-balancing. Moreover, explorative mortality endpoints reached the highest agreement and explorative endpoints capturing health-related quality of life no agreement, referring to the mutual relevance of endpoints for the risk-benefit-ratio and the benefit-harm-balancing.CONCLUSIONS:The missing information transparency of the assessment reports compared to the information offered within the early benefit assessment makes an assignment of endpoints with respect to the mutually relevant clinical trial sometimes troublesome. To warrant, in the long run, a broader confirmatory basis for decisions in health care supported by HTA, a closer inter-institutional cooperation of approval authorities and German HTA jurisdictions seems favorable.

scholarly journals The unpopularity of incentive-based instruments: what improves the cost–benefit ratio?

Public Choice ◽  
2018 ◽  
Vol 175 (1-2) ◽  
pp. 37-62 ◽  
Author(s):  
Isabelle Stadelmann-Steffen ◽  
Clau Dermont
Keyword(s):  
Cost Benefit ◽  
Benefit Ratio ◽  
Cost Benefit Ratio ◽  
The Cost

An Economic Evaluation of the Introduction of Vaccination Against Hepatitis a in a Peacekeeping Operation: The Case of the United Nations Protection Force in Yugoslavia

1994 ◽  
Vol 10 (3) ◽  
pp. 490-497 ◽  
Author(s):  
Tom Jefferson ◽  
Vittorio Demicheli ◽  
David Wright
Keyword(s):  
United Nations ◽  
Marginal Cost ◽  
Hepatitis A ◽  
Passive Immunization ◽  
Cost Benefit ◽  
Low Risk ◽  
Costs And Benefits ◽  
Benefit Ratio ◽  
Cost Benefit Ratio ◽  
The Cost

AbstractThe costs and benefits of vaccinating troops on United Nations tours in Yugoslavia against hepatitis A were compared. The marginal cost of one case of hepatitis A avoided by vaccination was calculated and compared with the marginal cost of achieving the same outcome by passive immunization. The cost-benefit ratio (medium estimate) for troops at low risk of contracting hepatitis A was 0.01 and for those at high risk was 0.03.Vaccinating troops against hepatitis A for a single deployment appears to be an inefficient procedure, especially in troops at low risk. However, in professional troops from countries of low hepatitis A endemicity who are likely to be involved in several operational deployments, vaccination becomes more efficient the more times the same troops are deployed.

Sign in / Sign up

Export Citation Format

Share Document